Insmed Inc Presents New Subgroup Analyses From Landmark Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis Demonstrate Consistency With Overall Trial Population Results At The CHEST 2024 Annual Meeting
Insmed Inc Presents New Subgroup Analyses From Landmark Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis Demonstrate Consistency With Overall Trial Population Results At The CHEST 2024 Annual Meeting
—Data Presented at the CHEST 2024 Annual Meeting—
—在2024年CHESt年會上呈現的數據—
BRIDGEWATER, N.J., Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. Posters with the details from these subgroup analyses can be found HERE. These data were presented at the CHEST 2024 Annual Meeting, held October 6-9 in Boston, along with several other presentations from across Insmed's respiratory portfolio.
新澤西州布里奇沃特，2024年10月8日 / PRNewswire / - 全球生物製藥公司Insmed Incorporated（納斯達克：INSM）今天在非囊性纖維化支氣管擴張症患者中評估布倫索卡替治療的全球性、隨機化、雙盲、安慰劑對照的III期ASPEN研究中，推出正面的突破性分組數據。 這些分組分析的詳細信息海報可以在此處找到。 這些數據於10月6日至9日在波士頓舉行的CHESt 2024年年會上進行展示，與Insmed呼吸學產品組合中的其他多個演講一起。
